204 related articles for article (PubMed ID: 23935131)
1. GH therapy and cancer risk in hypopituitarism: what we know from human studies.
Pekic S; Popovic V
Eur J Endocrinol; 2013 Nov; 169(5):R89-97. PubMed ID: 23935131
[TBL] [Abstract][Full Text] [Related]
2. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
[TBL] [Abstract][Full Text] [Related]
3. Controversies in the risk of neoplasia in GH deficiency.
Pekic S; Stojanovic M; Popovic V
Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):35-47. PubMed ID: 28477731
[TBL] [Abstract][Full Text] [Related]
4. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
5. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
Abs R; Bengtsson BA; Hernberg-Stâhl E; Monson JP; Tauber JP; Wilton P; Wüster C
Clin Endocrinol (Oxf); 1999 Jun; 50(6):703-13. PubMed ID: 10468941
[TBL] [Abstract][Full Text] [Related]
6. The value of IGF1 estimation in adults with GH deficiency.
Mukherjee A; Shalet SM
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S33-9. PubMed ID: 19684059
[TBL] [Abstract][Full Text] [Related]
7. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
[TBL] [Abstract][Full Text] [Related]
8. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
Feldt-Rasmussen U; Wilton P; Jonsson P; ;
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
[TBL] [Abstract][Full Text] [Related]
9. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
[TBL] [Abstract][Full Text] [Related]
10. Does the GH-IGF axis play a role in cancer pathogenesis?
Cohen P; Clemmons DR; Rosenfeld RG
Growth Horm IGF Res; 2000 Dec; 10(6):297-305. PubMed ID: 11161960
[TBL] [Abstract][Full Text] [Related]
11. Does growth hormone cause cancer?
Jenkins PJ; Mukherjee A; Shalet SM
Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factors in hypopituitary GH-deficient adults.
Verhelst J; Abs R
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S41-9. PubMed ID: 19684057
[TBL] [Abstract][Full Text] [Related]
13. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.
Spielhagen C; Schwahn C; Möller K; Friedrich N; Kohlmann T; Moock J; Kołtowska-Häggström M; Nauck M; Buchfelder M; Wallaschofski H
Growth Horm IGF Res; 2011 Feb; 21(1):1-10. PubMed ID: 21093334
[TBL] [Abstract][Full Text] [Related]
14. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
[TBL] [Abstract][Full Text] [Related]
15. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of recombinant human growth hormone in children.
Bell J; Parker KL; Swinford RD; Hoffman AR; Maneatis T; Lippe B
J Clin Endocrinol Metab; 2010 Jan; 95(1):167-77. PubMed ID: 19906787
[TBL] [Abstract][Full Text] [Related]
17. Acromegaly induced by growth hormone replacement therapy.
Karges B; Pfäffle R; Boehm BO; Karges W
Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
[TBL] [Abstract][Full Text] [Related]
18. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients.
Johannsson G; Touraine P; Feldt-Rasmussen U; Pico A; Vila G; Mattsson AF; Carlsson M; Korbonits M; van Beek AP; Wajnrajch MP; Gomez R; Yuen KCJ
J Clin Endocrinol Metab; 2022 Jun; 107(7):1906-1919. PubMed ID: 35368070
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update.
Gazzaruso C; Gola M; Karamouzis I; Giubbini R; Giustina A
J Clin Endocrinol Metab; 2014 Jan; 99(1):18-29. PubMed ID: 24217903
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
